Mar 26, 2013, 11.22 AM | Source: Reuters
Shares in Wockhardt gain 1.5 percent to 1,936.70 rupees after Bank of America-Merrill Lynch initiates coverage on the stock with a "buy" rating and a target price of Rs 2,565.
BofA-Merrill says the stock will benefit from a "likely" exit from a debt restructuring process, improved cash flows that could allow Wockhardt to turn debt-free by fiscal 2015, a recovery in domestic growth, and "consistent" earnings surprises.
In an interview to CNBC-TV18, SP Tulsian of sptuls
The US Food and Drug Administration (FDA) has give
The company had sought approval from the stakehold
Wockhardt has submitted a copy of minutes of the 1